Infectious Disease · Clinical trials
Clostridioides difficile Infection Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About clostridioides difficile infection — and why its trials are hard
Clostridioides difficile infection (CDI) is a toxin-mediated colitis, most often triggered by antibiotic-induced disruption of the gut microbiome, causing diarrhea that ranges from mild to fulminant. Its defining clinical challenge is recurrence: after an initial episode a substantial fraction of patients relapse, and risk compounds with each subsequent episode. Standard antibacterial therapy centers on oral vancomycin and the narrower-spectrum fidaxomicin, which is associated with lower recurrence. The monoclonal antibody bezlotoxumab, targeting toxin B, reduces recurrence when added to standard-of-care antibiotics. The most transformative recent advances restore the microbiome directly: Rebyota (fecal microbiota, live-jslm), approved in 2022, and Vowst (fecal microbiota spores, live-brpk / SER-109), approved in 2023 as the first orally administered microbiome therapeutic. These landmark approvals formalized microbiome-based prevention of recurrent CDI after decades of investigational fecal microbiota transplantation. Antibiotic stewardship, infection control, and diagnostics that distinguish colonization from active disease remain central to reducing CDI burden.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Vancomycin (oral) (Vancocin) | Longstanding CDI use (oral formulation approved 1986) | First-line treatment of CDI | Comparative CDI trials | Clinical cure of diarrhea | High initial cure rates; a standard comparator arm in CDI trials |
| Fidaxomicin (Dificid) | 2011 | Treatment of CDI | OPT-80-003/004 (phase 3) | Clinical cure; sustained response (recurrence) | Non-inferior cure to vancomycin with significantly lower recurrence (~15% vs ~25%) |
| Bezlotoxumab (Zinplava) | 2016 | Prevention of CDI recurrence (with standard-of-care antibiotics) | MODIFY I and MODIFY II | CDI recurrence through 12 weeks | Recurrence reduced to ~17% vs ~28% with placebo (about a 10-point absolute reduction) |
| Fecal microbiota, live-jslm (Rebyota) | 2022 | Prevention of recurrent CDI after standard antibiotic treatment (rectal administration) | PUNCH CD3 | Treatment success (absence of CDI diarrhea) at 8 weeks | ~71% success vs ~58% with placebo (Bayesian analysis) |
| Fecal microbiota spores, live-brpk (SER-109) (Vowst) | 2023 | Prevention of recurrent CDI after antibiotics (first oral microbiome therapeutic) | ECOSPOR-III | CDI recurrence up to 8 weeks | Recurrence 12% vs 40% with placebo (significant reduction) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in clostridioides difficile infection development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tolevamer — Phase 3 polymer toxin-binder trials | Failed to demonstrate non-inferiority; inferior clinical cure vs vancomycin and metronidazole | Non-antibiotic toxin-binding strategy achieved lower cure rates despite lower recurrence signal |
| Actoxumab (anti-toxin A) — MODIFY I/II | Added no recurrence benefit; actoxumab-containing arm discontinued | Anti-toxin A monoclonal, alone or with bezlotoxumab, provided no incremental efficacy over bezlotoxumab and raised safety concerns |
| Ridinilazole — Ri-CoDIFy (phase 3) | Failed to show superiority in sustained clinical response vs vancomycin | Did not meet the primary superiority endpoint despite earlier phase 2 promise |
Choosing the right endpoint
Primary endpoints that matter in clostridioides difficile infection trials
- Clinical cure — Resolution of diarrhea at end of treatment; primary measure of acute antibacterial efficacy
- CDI recurrence — Return of CDI diarrhea within a defined window (often 8-12 weeks); the key endpoint for prevention therapies
- Sustained clinical response — Composite of initial cure plus no recurrence, capturing durable benefit
- Treatment success (microbiome products) — Absence of CDI diarrhea requiring treatment through 8 weeks after intervention
How iNGENū runs clostridioides difficile infection trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Clostridioides difficile Infection clinical trials — FAQs
Why is recurrence such a problem in CDI?
How do Rebyota and Vowst differ?
Is fidaxomicin better than vancomycin?
Ready to discuss your clostridioides difficile infection trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal